Next 10 |
home / stock / srpt / srpt articles
RBC Capital Markets upgraded REGENXBIO Inc (NASDAQ:RGNX), a company focused on developing gene therapies. Recently, REGENXBIO reported ad...
In a significant trend, pharmaceutical companies in the U.S. introduced new drugs last year at prices 35% higher than in 2022, notably attributed t...
BeiGene (NASDAQ: BGNE) is expected to report its fourth-quarter 2023 results soon. BeiGene currently markets three internally discovered oncology p...
Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quart...
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday. Shares of Applied Materials, Inc. (NASDAQ: AMAT) rose sha...
Last Wednesday, REGENXBIO Inc (NASDAQ:RGNX) reported additional interim safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE tria...
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced data from Part B of the MOMENTUM study (Study SRP-5051-201) Phase 2, multi-ascending dose tri...
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product revenue of $1.145 billion. The Cambridge, Mass...
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Acuity Brands, Inc. (NYSE: AYI) rose sharply Tuesd...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
2024-04-06 08:45:00 ET The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure for all illnesses. Further, biotechs often deliver better-than-average...
2024-03-19 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-13 08:00:00 ET Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX) , another biotech, the company is making headway with a gene therapy for Duchenne muscular dystr...